Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 6, 1998

View Archived Issues

M-5011, a novel NSAID, shown to inhibit vertebral bone loss in arthritic rats

SmithKline Beecham to market smoking cessation patch in China

SB acquires stake in Romanian pharmaceutical market

Inex to focus internal R&D program on three cancer drug product candidates

Aurora Biosciences completes first stage of UHTSS for Warner-Lambert

Canadian research team uncovers genetic basis of epileptic disorder

Antitumor agents with high potency and selectivity under evaluation at Shionogi

Banyu patents new series of NPY antagonists for obesity, bulimia, diabetes

Tanabe presents new antidiabetic agents

Basic research in the field of vitronectin antagonists revealed by HMR

Glycylcycline antibiotic enters clinical testing

Ono discloses compounds with high binding affinity for prostanoid EP4 receptors

Dopamine reuptake inhibitors synthesized at Pola, useful for Parkinson's disease

HMR-3647: the first ketolide to reach advanced-stage clinical testing

Preclinical profile of BI-397, a promising new glycopeptide antibiotic

MiKasome phase I data presented at ICAAC; development update

Lilly glycopeptide advances to phase II for various resistant infections

Novel acid-stable macrolides from Abbott presented at ICAAC

Abbott obtains new ketolides with improved activity against MLS-resistant strains

New lead anti-HIV compound discovered by Italian university researchers

The PAF antagonist MFH-1 shows potential as an adjunct in the therapy of AIDS

Potent, orally absorbed HIV-1 protease inhibitors selected from series of azadipeptides

New broad-spectrum anti-MRSA pyrrolidinone cephalosporin and water-soluble prodrug from Roche

La Jolla enrolls patients in phase II/III trial for lupus treatment

Osiris begins clinical trials with hMSC product in cancer patients

Lidak proposes name change to Avanir

Centocor exercises option for license to HuMAb-Mouse technology

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...